Which country specifically produces selumetinib?

Selumetinib is a highly targeted oral MEK inhibitor and is one of the important representatives of modern molecular targeted therapy drugs. The drug was originally developed by Array BioPharma, an American biopharmaceutical company that focuses on the research and development of targeted therapies for cancer and rare diseases and has a rich background in small molecule drug research. Selumetinib completed early pharmacological research and preclinical development in the United States, and later attracted the attention of multinational pharmaceutical giant AstraZeneca for its potential in the field of rare diseases. In 2011, AstraZeneca obtained the global development and commercialization authorization for the drug and led its subsequent large-scale clinical development, registration application and marketing.

Therefore, strictly speaking, selumetinib is an original research drug originating in the United States, but its global marketing and drug registration are mainly responsible for AstraZeneca, headquartered in London, England. Currently, selumetinib has been approved for use in pediatric patients with neurofibromatosis type 1 (NF1) combined with plexiform neurofibromas (PN) in many countries and regions including the United States, the European Union, Japan, and China. The trade name is "KOSELUGO", the Chinese name is "KOSELUGO", and it is registered in China as "Selumetinib Hydrogen Sulfate Capsules".

As a highly precise molecular targeted therapy, the global launch of selumetinib marks a breakthrough in the expansion of targeted therapy from tumor treatment to rare genetic diseases. Its industrial chain covers the synthesis of raw materials, capsule preparation production, packaging and global logistics. It is mainly completed by AstraZeneca's branches in many places. The production bases are located in the United Kingdom, Sweden and the United States. The specific distribution is based on the drug supervision and market strategies of different countries.

Reference materials:https://www.koselugo.com